Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Gemma Collins Discontinues Mounjaro Over Pain, Switches to Microdosing
S
Shotlee
Health & Wellness Team
3 min read
Preparing your Shotlee experience
Gemma Collins stopped taking Mounjaro due to experiencing severe pain, which she initially feared was connected to the weight loss medication. After a break, she has decided to resume treatment through microdosing to minimize potential side effects while continuing her weight loss journey.
Gemma Collins has shared that she is now microdosing Mounjaro, a decision made after concerns that the weight loss injections were causing significant health issues.
Last month, the former TOWIE star told the Daily Mail about a 'gallbladder attack' she experienced in August, which caused her to collapse due to intense pain.
Having reduced from a size 26 to a size 20 and losing 3.5 stone since starting the injections, Gemma took a break before deciding to resume the treatment.
'I had to pause the injections for a while because of a gallbladder attack in August. However, I've been assured that it's not actually related to Mounjaro,' Gemma informed The Mirror.
She added, 'After a break and careful management of my diet, I'm considering microdosing. I believe microdosing will help minimize any adverse reactions.' Health tracking apps like Shotlee can help monitor any side effects.
Collins followed the recommended approach of gradually increasing her dosage, starting from 2.5mg and eventually reaching the maximum of 15mg per week.
Now, she has confirmed that she intends to stick with the 2.5mg dose, as it proved to be the most effective for her.
Describing the medication as 'life-changing,' she stated, 'I've managed to lose about 3½ stone and have successfully kept it off. I feel great. I'm not aiming to be extremely thin; that's not my goal. My focus is on improving my health, and I'm moving in the right direction.'
Her ultimate goal is to lose a total of 6 stone from her initial weight. However, she is not in a hurry to lose the weight rapidly.
According to Dr. Babak Ashrafi of Superdrug, one of the reported common side effects of Mounjaro is gallstones.
On the company website, Dr. Ashrafi explained, 'Gallbladder issues, such as gallstones or inflammation (cholecystitis), are rare but potentially serious side effects of Mounjaro.'
'GLP-1 inhibitors, like Mounjaro, can lead to gallbladder problems by reducing the levels of cholecystokinin, a hormone essential for healthy gallbladder function.'
The Mounjaro patient information leaflet also lists gallstones as a possible side effect.
While Collins has proudly showcased her weight loss achievements, she also experienced an immediate side effect from the injections.
Gemma expressed concern that her weight loss was making her 'look older.' She shared an honest post on Instagram, pointing out the appearance of crow's feet.
She previously mentioned: 'I'm not sure what's happening to me; it seemed to happen overnight. It's been a year since I had any cosmetic procedures.'
'I'm not sure if it's due to the weight loss. I don't have 'Ozempic face' yet, but that would be ideal right now.'
'I've always had a fuller face. I appreciate the expressions around my eyes and want to maintain a natural look. But something isn't right.'
'What's going on? I'm 44, but this is taking it to a level I never anticipated.'
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from Daily Mail Online
View Original Article
An affordable and readily accessible medication is gaining attention as a potential solution for curbing alcohol cravings, drawing comparisons to the way GLP-1 drugs manage food cravings. Naltrexone, by impacting dopamine-reward pathways, reduces the satisfying feeling associated with alcohol consumption, thus diminishing the desire for it. Research and anecdotal evidence suggest it could be a game-changer for many.
Mounjaro, a drug by Eli Lilly, is set to be included in China's state-run health insurance program for individuals with type 2 diabetes starting January 1. This inclusion aims to improve access to the medication, although increased sales may be balanced by reduced prices. The drug was introduced in China earlier this year.
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨